Desire for Better
As the mRNA market shifts toward cost efficiency beyond the COVID‑19 era, demand for optimized COGS has become essential.
HanmiCap® is a next‑generation 5′ capping material delivering high performance and cost efficiency through process optimization and IP‑safe structural design.
The development of HanmiCap® is informed by peer‑reviewed research on trinucleotide 5′‑cap analogs. The research provides insights into how structural
modification may influence capping efficiency, mRNA stability, and translation. These findings help guide HanmiCap® as a proprietary 5′‑capping material for
mRNA applications.
HanmiCap® - Proprietary 5' Cap analogs for in vitro transcription
We have developed proprietary 5' capping materials (HanmiCap®) demonstrating cost-competitiveness and high performances in mRNA R&D.
The reduced cost of HanmiCap® has been achieved through the process optimization in the phosphorylation and purification steps.
-
01n cap dependent translation manner, specific non-polarity caused by R1 or R2 groups could affect translation level of the capped mRNA. R groups stand for modified moieties.
-
02Due to the introduction of R1 or R2 group, phosphorylation and purification steps are reduced.
-
03To reduce innate immunity for exogenous mRNA.
-
04Complementary binding to TC DNA template.